Problem & Market: The liver produces 800 ml of bile daily; Cholestasis, caused by autoimmune diseases or unhealthy lifestyles, leads to serious liver injury and metabolic issues, necessitating 10% of liver transplants. Targeting chronic cholestatic diseases without effective treatments, we address a $2.5B market for 370,000 patients in Europe, the US, China, and Japan. Solution: Our novel therapeutic target uses liver-specific GalNAc siRNA, preventing liver injury in cholestasis models. This approach provides improved efficacy and safety. Team: Led by Dr. Felix Baier (Project lead), with Dr. Niclas Melin (GalNAc technology), Professors Deborah Stroka, Daniel Candinas (medical/scientific oversight), and Corina Krummenacher (biomedical technician).
